average weight loss glp-1 drugs Growth, Volume, Price: The Skinny on Medications - A monthly GLP-1 dose could

Retatrutide should be considered a second-line or specialized first-line agent for complex cases once it gains regulatory approval

In clinical trials, the results were impressive: a median survival rate of 177.1 months for the early treatment Zycubo cohort compared with only 17.6 months for the untreated external cohort

Ko GT, Chan WB, Chan JC, et al

Complete Chain of Custody No dropshipping

These effects contribute to weight loss that varies by agent and dosetypically ranging from 5-8% with liraglutide 3 mg (Saxenda), up to 15% with semaglutide 2.4 mg (Wegovy), and potentially up to 20% with higher doses of tirzepatide (Zepbound)

This perspective explores the practice implications for managing patients living with obesity and/or diabetes who are taking GLP-1 agonists by describing the impact of GLP-1 agonists